Payment overview · 2025
General Payments
$78.84
3 reported records · 3 companies
Healthcare provider profile · identity verified
Joy L. Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE GIRARDEAU, MO · NPI 1184616120
Verified facts
What the public records show
CMS Open Payments records show Joy L. Johnson, M.D. received $78.84 in general payments during 2025 across 3 reported records.
Edwards Lifesciences Corporation accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $30.64 | 38.9% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $29.72 | 37.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.48 | 23.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $78.84 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $30.64 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $29.72 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 384 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 334 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 54 |
| Omeprazole | Omeprazole | 219 | 54 |
| Metformin Hcl Er | Metformin Hcl | 214 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 43 |
| Lisinopril | Lisinopril | 201 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 38 |
| Montelukast Sodium | Montelukast Sodium | 170 | 32 |
| Gabapentin | Gabapentin | 163 | 39 |
| Losartan Potassium | Losartan Potassium | 163 | 38 |
| Furosemide | Furosemide | 161 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 34 |
| Metformin Hcl | Metformin Hcl | 159 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 35 |
| Simvastatin | Simvastatin | 150 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 143 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 27 |
| Meloxicam | Meloxicam | 127 | 35 |
| Carvedilol | Carvedilol | 123 | 23 |
| Sertraline Hcl | Sertraline Hcl | 111 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 18 |
| Allopurinol | Allopurinol | 81 | 16 |
| Rybelsus | Semaglutide | 75 | 13 |
| Buspirone Hcl | Buspirone Hcl | 72 | 14 |
| Ozempic | Semaglutide | 68 | 12 |
| Atenolol | Atenolol | 66 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 15 |
| Eliquis | Apixaban | 65 | 15 |
| Linzess | Linaclotide | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 61 | 15 |
| Trazodone Hcl | Trazodone Hcl | 60 | 13 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Nifedipine Er | Nifedipine | 58 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 14 |
| Glimepiride | Glimepiride | 51 | 14 |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 50 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Spironolactone | Spironolactone | 48 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 12 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Clonidine | Clonidine | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 20 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Glipizide | Glipizide | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78.84 · 3 records | Edwards Lifesciences Corporation | BEYFORTUS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, QUTENZA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error